Fundación Santandereana de Diabetes y Obesidad Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2005
NCT00428727
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Alternative names

Fundación Santandereana de Diabetes y Obesidad (FUSANDE)

Active Ingredients

Drugs in Phase 3 Trials (1)

nitric oxide (inomax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1